BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 27835037)

  • 1. Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
    Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Hendrieckx C; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Speight J; Trawley S; Ward GM; Roy A; Jones TW; O'Neal DN
    Diabetes Technol Ther; 2016 Dec; 18(12):772-783. PubMed ID: 27835037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.
    Nimri R; Bratina N; Kordonouri O; Avbelj Stefanija M; Fath M; Biester T; Muller I; Atlas E; Miller S; Fogel A; Phillip M; Danne T; Battelino T
    Diabetes Obes Metab; 2017 Apr; 19(4):553-561. PubMed ID: 27981804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
    Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manual Closed-Loop Insulin Delivery Using a Saddle Point Model Predictive Control Algorithm: Results of a Crossover Randomized Overnight Study.
    Guilhem I; Penet M; Paillard A; Carpentier M; Esvant A; Lefebvre MA; Poirier JY
    J Diabetes Sci Technol; 2017 Sep; 11(5):1007-1014. PubMed ID: 28677416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
    Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
    Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
    Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
    Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
    Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
    Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.
    Brown SA; Breton MD; Anderson SM; Kollar L; Keith-Hynes P; Levy CJ; Lam DW; Levister C; Baysal N; Kudva YC; Basu A; Dadlani V; Hinshaw L; McCrady-Spitzer S; Bruttomesso D; Visentin R; Galasso S; Del Favero S; Leal Y; Boscari F; Avogaro A; Cobelli C; Kovatchev BP
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3674-3682. PubMed ID: 28666360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multinational Home Use of Closed-Loop Control Is Safe and Effective.
    Anderson SM; Raghinaru D; Pinsker JE; Boscari F; Renard E; Buckingham BA; Nimri R; Doyle FJ; Brown SA; Keith-Hynes P; Breton MD; Chernavvsky D; Bevier WC; Bradley PK; Bruttomesso D; Del Favero S; Calore R; Cobelli C; Avogaro A; Farret A; Place J; Ly TT; Shanmugham S; Phillip M; Dassau E; Dasanayake IS; Kollman C; Lum JW; Beck RW; Kovatchev B;
    Diabetes Care; 2016 Jul; 39(7):1143-50. PubMed ID: 27208316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 17. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.
    Renard E; Farret A; Kropff J; Bruttomesso D; Messori M; Place J; Visentin R; Calore R; Toffanin C; Di Palma F; Lanzola G; Magni P; Boscari F; Galasso S; Avogaro A; Keith-Hynes P; Kovatchev B; Del Favero S; Cobelli C; Magni L; DeVries JH;
    Diabetes Care; 2016 Jul; 39(7):1151-60. PubMed ID: 27208331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
    Rodbard D
    Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.